Lack of preservation of insulin gene expression by a Glucagon-Like Peptide 1 agonist or a Dipeptidyl Peptidase 4 inhibitor in an in vivo model of glucolipotoxicity

This publication has 36 references indexed in Scilit:

• New treatments in type 2 diabetes: a focus on the incretin‐based therapies
  Clinical Endocrinology, 2009
• Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction
  Endocrine Reviews, 2008
• Cyclical and Alternating Infusions of Glucose and Intralipid in Rats Inhibit Insulin Gene Expression and Pdx-1 Binding in Islets
  Diabetes, 2008
• Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice
  Diabetes, 2008
• Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice
  The Journal of Pharmacology and Experimental Therapeutics, 2006
• The biology of incretin hormones
  Cell Metabolism, 2006
• Palmitate Inhibition of Insulin Gene Expression Is Mediated at the Transcriptional Level via Ceramide Synthesis
  Journal of Biological Chemistry, 2003
• Minireview: Secondary -Cell Failure in Type 2 Diabetes--A Convergence of Glucotoxicity and Lipotoxicity
  Endocrinology, 2002
• Insulinotropic Hormone Glucagon-Like Peptide 1 (GLP-1) Activation of Insulin Gene Promoter Inhibited by p38 Mitogen-Activated Protein Kinase
  Endocrinology, 2001
• U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group
  Diabetes, 1995